Abstract:【Objective】 To investigate the effects of rosuvastatin calcium(RS) combined with piracetam(Pir) on cognitive function and event-related potential(ERP) latency in patients with vascular dementia(VD) aged >60 years. 【Methods】 A total of114 VD patients older than 60 years old(January 2018 to November 2020) were selected from our hospital for a prospective randomized parallel controlled study. According to random number table method, they were divided into group A(n=57) and group B(n=57). Group B received Pir, and group A received RS combined with Pir. The total response rate, MMSE score, ADL score, ERP latency, amplitude, serum superoxide dismutase(SOD), malondialdehyde(MDA) and lipid peroxide(LPO) levels were compared between the two groups before treatment and 6 months after treatment. 【Results】 The total effective rate of group A(96.49%,55/57) was higher than that of group B(82.46%, 47/57)(P<0.05). After 6 months of treatment, the MMSE and ADL scores of group A were higher than those of group B(P<0.05). After 6 months of treatment, the latency of ERP in group A was lower than that in group B, but its amplitude was higher than that in group B(P<0.05). After 6 months of treatment, the serum MDA and LPO levels in group A were lower than those in group B, and the serum SOD levels were higher than those in group B(P<0.05).【Conclusion】 RS combined with Pir is effective in the treatment of VD patients aged >60 years. It can effectively improve the cognitive function of patients, improve the ability of daily living, and effectively regulate the levels of MDA, LPO and SOD in serum, and alleviate oxidative stress.
